873591--2/27/2007--MEDIMMUNE_INC

related topics

{product, candidate, development}

{product, liability, claim}

{customer, product, revenue}

{property, intellectual, protect}

{stock, price, operating}

{product, market, service}

{personnel, key, retain}

{operation, international, foreign}

{cost, regulation, environmental}

{regulation, government, change}

{acquisition, growth, future}

Our revenues are largely dependent on sales of Synagis. The seasonal nature of a significant portion of our business causes significant fluctuations in our quarterly operating results. The successful commercialization of the refrigerated formulation of FluMist is critical to the future of our influenza vaccine business. The commercial success of our influenza vaccine business is uncertain and we may not be able to recover the value of our investment. Loss of our litigation against Sun Pharmaceutical Industries Limited would be detrimental to our Ethyol sales. Government involvement may limit the commercial success of our influenza vaccine business. We may not be able to bring our product candidates to market. A significant portion of our business is dependent on third parties. As a U.S. government contractor, we are required to comply with a number of rules and regulations and may be exposed to unique risks. Defending product liability claims could be costly and divert focus from our business operations and product recalls may be necessary. We may not be able to meet the market demand for our products. We may lose product due to contamination of our raw materials and other difficulties in the manufacturing process. Certain developments in the United Kingdom could have an adverse effect on our ability to manufacture our products. Reimbursement by government and third-party payors is critical for the success of our products. Our reliance upon a limited number of pharmaceutical wholesalers and distributors could affect the ability to sell our products. Obtaining and maintaining regulatory approvals to develop, manufacture and market our products is costly and time consuming. Patent protection for our products may be inadequate or costly to enforce. If we fail to obtain and maintain any required intellectual property licenses from third parties, our product development and marketing efforts will be limited. Technological developments by competitors may render our products obsolete. We are subject to numerous complex laws and regulations and compliance with these laws and regulations is costly and time consuming. We cannot control the use of our products. We may not be able to hire or retain highly qualified personnel or maintain key relationships. If we fail to manage our growth properly, the business will suffer. Fluctuations in our common stock price over time could cause stockholders to lose investment value. Changes in foreign currency exchange rates or interest rates could result in losses.

Full 10-K form ▸

873591--2/27/2007--MEDIMMUNE_INC_/DE